Connect with us

Technology

GenBio AI Releases Phase 1 of World’s First Digital Organism to Transform Medical Research

Published

on

PALO ALTO, Calif., Dec. 19, 2024 /PRNewswire/ — Just as the transistor and microscope unlocked new waves of discovery, today, GenBio AI opens the doors to a new era of scientific exploration with Phase 1 of the world’s first AI-Driven Digital Organism (AIDO).

In this first phase, scientists will have access to not one, but six groundbreaking models that can simulate, program, and predict complex biological outcomes for DNA, RNA, Protein, Protein Structure, Single Cell Expression, and Evolutionary Information.

Unlike earlier models that focus on specific aspects of a multi-cellular organism, GenBio AI takes a holistic approach where multiscale foundation models are built in modules and integrated into a single system. These State-Of-The-Art models are unprecedented in their capabilities:

They are the fastest and most efficient in the market – solving up to 300 diverse tasks simultaneously, compared to one to two tasks.They are the only ones intentionally built to interact with each other – finally tackling biology and AI’s research silo problem.They allow biological data of all types and scales to be utilized to distill holistic and comprehensive knowledge of how living systems work – the first time this has ever been possible.

GenBio AI is set to fuel an unprecedented era of discovery across molecular, cellular, and organism levels. These “building block” Foundational Models are just the first phase on the company’s road map to the world’s first AIDO. More details are expected in the year ahead.

Professor Eric Xing, Co-Founder and Chief Scientist of GenBio AI, said: “GenBio will usher in a new era of medical and life science—through a paradigm shift powered by next-generation Generative AI technology beyond what has already brought us disruptive results such as ChatGPT. Our transformative technology allows biological data of all types and scales to be utilized to distill holistic and comprehensive knowledge of how living systems work. Therefore, multiscale biological complexities are no longer barriers but opportunities for breakthrough insights.”

The company’s world-class and internationally recognized team of scientists, scholars, and engineers are leading experts in AI, machine learning, high-performance computing, and computational and experimental biology. The team published all six technical papers detailing their novel approach to creating the world’s first AIDO at the 38th Annual Conference on Neural Information Processing Systems (NeurIPS) – the top AI research conference.  

By sharing this work, GenBio aims to help guide the community forward, enabling experts to understand the possibilities to observe, experiment with, and eventually program living systems with unprecedented precision across molecular, cellular, and systemic levels.

Breaking Down Biological Barriers – Detailing GenBio AI’s Models

GenBio AI is the first company to release multifunctional models covering mainstream biological data – namely DNA, RNA, Protein, and Cell – and are poised to empower researchers to drive the next breakthroughs in medicine, drug discovery, and longevity research.

GenBio AI’s AIDO-DNA Foundation Model features 7 billion parameters trained on data from 796 different species. This State-Of-The-Art model surpasses previous encoder-only architectures without requiring new data, indicating that new scaling rules may be essential for creating optimal DNA language models.

GenBio AI’s AIDO-RNA Foundation Model, with 1.6 billion parameters, is the largest and most comprehensive model of its kind. RNA has emerged as a key technology for vaccine and drug design over the last several years and GenBio AI’s model provides faster results for structure prediction, genetic regulation, and RNA sequence design.

GenBio AI’s AIDO-Protein Foundation Model is one of the largest and most computationally efficient models of its kind – facilitating deeper exploration of these essential biological elements while maintaining scalability.

GenBio AI’s AIDO-Single Cell Model includes a range of models with 3 million, 10 million, 100 million, and 650 million parameters, pre-trained on a dataset of 50 million human cells. This set of cell foundation models are scalable and the first capable of processing the entire human transcriptome as input without truncation or sampling techniques, allowing it to learn precise and comprehensive representations of the complete transcriptional landscape of human cells.

Dr. Le Song, Co-Founder and Chief Technology Officer at GenBio AI, said: “What we have built is revolutionary because our integrated system will use these state-of-the-art models to create interactive digital versions of biological systems that can be safely experimented on and precisely modified. This technology lets us program biology the way we program computers, opening up possibilities we’ve never had before in medicine and biotechnology.”

Professor Xing continues: “Even before their integration into the AIDO system, each Foundational Model from the collection stands out already as a best-of-its-kind among their respective peers. GenBio AI does not just train best soloists, it is building an orchestra made of a herd of the best soloists.”

Transforming Medical Research and Drug Development

GenBio AI’s Digital Organism will revolutionize three critical areas:

Drug Discovery: Traditional drug development requires $1-2 billion and sees a 90% failure rate. AIDO will enable researchers to design and test millions of potential treatments in hours, enabling the prediction and analysis regarding how they affect entire biological systems before entering a lab.

Disease Understanding: With deaths from lung cancer, heart disease, and Alzheimer’s rising across the G20, scientists need new tools to understand these conditions. AIDO will provide researchers with a foundational AI model to build a better understanding of disease mechanisms and potential interventions.

Personalized Medicine: With adverse drug reactions ranking among the top six causes of death worldwide, the need for personalized treatment is critical. AIDO will allow doctors to create digital patient twins, potentially accelerating the development of safe, effective treatment plans while minimizing adverse drug interactions.

Global Expertise, Global Impact

GenBio AI’s achievement represents a collaboration of world-renowned scientists from leading institutions, including Carnegie Mellon University (CMU), Stanford, the Weizmann Institute of Science, and MBZUAI. Senior Scientific Fellows, including Eran Segal and Fabian Theis, also add to the company’s robust team of internationally recognized experts.

Headquartered in Palo Alto with satellite labs in Paris and Abu Dhabi, GenBio AI takes a global approach to solving these fundamental challenges in biology. The intellectual foundation of this breakthrough was detailed in the six peer-reviewed papers presented at NeurIPS. 

Professor Eran Segal, Department of Computer Science, Weizmann Institute of Science says: “GenBio AI’s six multiscale foundation models are a leap forward in our ability to understand and predict biological phenomena. We now have the capacity to uncover systemic insights into how organisms function. This is transformative for genomics research, where the ability to simulate and program at multiple scales opens new avenues for precision medicine and disease intervention.”

Professor Fabian Theis, Director of the Institute for Computational Biology at Helmholtz Munich and Professor at the Technical University of Munich says: “GenBio AI’s achievement in creating scalable state-of-the-art models on multiple scales is a game-changer. This technology not only accelerates our ability to explore cellular dynamics but also bridges the gap between molecular and systems biology, unlocking unprecedented opportunities for disease modeling and therapeutic innovation.”

A New Chapter in Biological Science

The launch of GenBio AI marks the beginning of a new era in biological science. This isn’t just a new tool for research – it’s a fundamental transformation in how we interact with and understand living systems.

Explore the research:

Toward AI-Driven Digital Organism: A System of Multiscale Foundation Models for Predicting, Simulating and Programming Biology at All Levels

Accurate and General DNA Representations Emerge from Genome Foundation Models at Scale

Mixture of Experts Enable Efficient and Effective Protein Understanding and Design

Balancing Locality and Reconstruction in Protein Structure Tokenizer

Retrieval Augmented Protein Language Models for Protein Structure Prediction

A Large-Scale Foundation Model for RNA Function and Structure Prediction

Scaling Dense Representations for Single Cell with Transcriptome-Scale Context

About GenBio AI

GenBio.AI, Inc. (GenBio AI) is an innovative global startup dedicated to developing the world’s first AI-driven Digital Organism, an integrated system of multiscale foundation models for predicting, simulating, and programming biology at all levels.

Our goal is to achieve comprehensive, actionable empirical understandings of the mechanisms underlying all organismal physiologies and diseases. This will pave the way for a new paradigm in drug design, bio-engineering, personalized medicine, and fundamental biomedical research, all powered by Generative Biology.

Our founding team consists of world-renowned scientists and researchers in AI and Biology from prestigious institutions such as CMU, MBZUAI, WIS, alongside prominent financial investors.

GenBio AI, a true global effort from day one, is establishing offices in Palo Alto, Paris, and Abu Dhabi.

For more information about GenBio AI and AIDO, visit GenBio.AI.

Photo – https://mma.prnewswire.com/media/2576977/GenBio_AI_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/genbio-ai-releases-phase-1-of-worlds-first-digital-organism-to-transform-medical-research-302335861.html

Continue Reading

Technology

Clever Closings Expands Its Digital Title and Escrow Service to 11 States, With Two More Planned in 2026

Published

on

By

Clever Real Estate’s closings division has added eight markets since June 2025, with escrow leaders bringing 250 years of combined title and settlement experience.

ST. LOUIS, Sept. 30, 2026 /PRNewswire/ — Clever Closings, the digital title and escrow division of Clever Real Estate, is now live in 11 states, up from three in June 2025, and expects to open Ohio and Pennsylvania before the end of the year. The expansion will put the division in 13 states less than three years after it began closing transactions.

Clever Closings places licensed local branch managers in every market, several with more than two decades of experience in their state, while intake, processing, and post-closing run centrally on one national platform. Every party to a transaction gets a direct line to the person running the file and a response within two business hours. Escrow staff compensation is tied directly to client survey scores, not just the number of files closed, a structure that is rare in the title industry.

Clever Closings takes a tech-forward approach to title and escrow, running every file on a single digital platform. Agents, buyers, sellers, and loan officers see every update in real-time, without the need to call or email for updates. Documents and messages are encrypted, and clients can deposit earnest money from their phone. Built-in fraud protection verifies each party’s ID against public records and screens wire instructions before any money moves.

“Title has historically been an office-heavy business, and that overhead gets passed to everyone in the transaction,” said Tony Chahal, President of Agent Network and Closings at Clever Real Estate. “We built the opposite. We use AI and our digital platform to handle the document review, status updates, and wire screening that take up most of a traditional escrow officer’s day, so our licensed local experts can focus on the parts of a closing that need a person. That is how we can serve any local market without opening a dozen offices.”

Clever Closings currently operates in Arizona, California, Colorado, Florida, Georgia, Illinois, Michigan, North Carolina, South Carolina, Tennessee, and Texas. Ohio and Pennsylvania are on track to launch this year, which will put Clever Closings in markets accounting for roughly 60% of U.S. home sales, according to Redfin data. The division is on pace to grow closed transactions nearly 70% in 2026 and has already surpassed its 2025 total.

As a result of Closings’ rapid growth, Clever promoted Chahal to President of Agent Network and Closings in July 2026, where he oversees the platform’s 13,000 active agents, in addition to the title and escrow business he founded in 2023. Before Clever, Chahal served as Head of Strategic Relationships at HomeLight, where he led the go-to-market strategy and a national sales organization across the company’s trade-in, cash offer, and closing services businesses.

“Clever is a vertically integrated platform built to make great agents dramatically more productive,” said Clever Co-Founder and CEO Luke Babich. “The average agent in this industry closes two transactions a year. Agents in our elite partner program close 21. We’re aligning our organization to keep delivering tech, services like Closings, and high-quality lead flow that help great agents build a great business.”

Agents at Compass, RE/MAX, Keller Williams, eXp, and Coldwell Banker have closed transactions through Clever Closings. Chahal credits the division’s 90% five-star rating to hiring licensed local experts in each state rather than staffing new markets remotely. The division is recruiting escrow officers and branch managers in Ohio and Pennsylvania ahead of launch.

Learn more at: https://www.cleverclosings.com

About Clever Closings

Clever Closings is the title and escrow division of Clever Real Estate, built to give real estate agents and their clients a modern closing experience. Every party gets real-time visibility into the transaction, encrypted document handling and messaging, digital earnest money deposits, and a choice of in-person, mobile notary or remote online notarization. The platform is SOC 2 Type II and ISO 27001 certified and operates under ALTA Best Practices. Clever Closings is live in 11 states, with Ohio and Pennsylvania launching in 2026.

About Clever Real Estate

Clever Real Estate allows sellers to compare top-rated discount real estate brokers and low-commission realtors in their local area. Clever’s content reaches over 12 million readers annually, and its nationwide agent matching service has a 4.9-star Trustpilot rating across more than 4,500 customer reviews. Since launching in 2017, Clever has reached over $17.3 billion in real estate sold, matched over 271,000 customers with realtors, and saved consumers over $250 million on commission fees. Clever’s network spans over 13,000 agents across all 50 states.

CONTACT:
Nicole Lehman
Clever Real Estate
423685@email4pr.com
724-719-0406

View original content to download multimedia:https://www.prnewswire.com/news-releases/clever-closings-expands-its-digital-title-and-escrow-service-to-11-states-with-two-more-planned-in-2026-302893796.html

SOURCE Clever Closings

Continue Reading

Technology

Recon Technology, Ltd Reports Financial Year Results for Fiscal Year 2026

Published

on

By

BEIJING, Sept. 30, 2026 /PRNewswire/ — Recon Technology, Ltd (NASDAQ: RCON) (“Recon” or the “Company”), a China-based independent solutions integrator in the oilfield service and environmental protection, electric power and coal chemical industries, today announced its financial results for fiscal year 2026.

Fiscal Year Ended June 30, 2026 Financial Highlights:

Total revenue increased by approximately RMB43.6 million ($6.4 million) or 65.8% to RMB109.9 million ($16.2 million) for the year ended June 30, 2026 from RMB66.3 million ($9.8 million) for the same period in 2025.Gross profit increased to RMB36.5 million ($5.4 million) for the year ended June 30, 2026, from RMB15.2 million ($2.2 million) for the same period in 2025.Gross margin increased to 33.2% for the year ended June 30, 2026 from 23.0% for the same period in 2025.Net loss was RMB31.6 million ($4.7 million) for the year ended June 30, 2026, a decrease of RMB12.1 million ($1.8 million) from net loss of RMB43.7 million ($6.4 million) for the same period of 2025.

 

For the Years Ended

June 30,

Percentage

2026

2025

Increase /(Decrease)

 Change

(in RMB millions, except earnings per share; differences due
to rounding)

Revenue

RMB

109.9

RMB

66.3

RMB

43.6

65.8

%

Gross profit

36.5

15.2

21.3

139.4

%

Gross margin

33.2

%

23.0

%

10.2

%

—

Net loss

(31.6)

(43.7)

(12.1)

27.6

%

Net loss per share – basic and diluted

(266.52)

(936.18)

(669.66)

71.5

%

Management Commentary

Mr. Shenping Yin, Founder and Chief Executive Officer of Recon, commented: “Fiscal 2026 marked a significant turning point for Recon. Revenue increased by 65.8% to RMB109.9 million, and gross margin was lifted to 33.2%. These factors, when combined, narrowed our net loss compared to the previous year. The primary growth driver was our strategic expansion into overseas oilfield projects.

We are pleased to announce that we have reached a significant milestone that we have been working towards for several years. On 28 September 2026, we held a ceremony to mark the commencement of operations at our waste plastic chemical recycling plant in Weifang, Shandong Province. The plant has been designed to process 40,000 tons of low-value waste plastics per year, with an expected output of 30,000 tons of pyrolysis oil and 6,000 tons of carbon residue. This strategic partnership provides Recon with a solid foundation in the circular economy, offering a new growth opportunity in addition to our core oilfield services.

As we look ahead to fiscal 2027, our strategic priorities are clear as we will bring the chemical recycling plant to commercial production, extend our overseas and offshore oilfield footprint, and rebuild our domestic service capabilities. Oil price volatility and broader macroeconomic conditions continue to present challenges, however, we enter the new year with a more diversified business portfolio, a strengthened margin profile and a diligent cost structure. These elements, we believe, will underpin sustainable, long-term growth for our shareholders.”

Fiscal Year Ended 2026 Financial Results:

Revenue

Total revenues for the year ended June 30, 2026 were approximately RMB109.9 million ($16.2 million), an increase of approximately RMB43.6 million ($6.4 million) or 65.8% from RMB66.3 million ($9.8 million) for the same period in 2025.

Revenue from automation product and software increased by RMB35.6 million ($5.3 million) or 104.5%. The increase was primarily driven by a RMB44.2 million revenue increase from overseas oilfield projects, partially offset by an RMB8.6 million decline in domestic business. The overseas revenue growth benefited from a phase-II oilfield capacity construction of a major overseas automation maintenance project. The domestic business decline was mainly due to reduced maintenance efforts in the domestic market during the period, as our focus shifted towards overseas projects. Going forward, the Company will reallocate personnel from overseas to strengthen domestic market maintenance services.Revenue from equipment and accessories increased by RMB9.4 million ($1.4 million) or 51.2%. The increase in revenue from equipment and spare parts was primarily driven by rising demand for new purchases and maintenance of such items. This was due to the ongoing need of domestic oilfield clients to maintain stable production levels.Revenue from oilfield environmental protection increased by RMB2.0 million ($0.3 million) or 19.4% primarily due to an increase in the settlement prices for some wastewater treatment clients.Revenue from platform outsourcing services decreased by RMB3.5 million ($0.5 million) or 100.00%. FGS’s operations were materially and adversely affected by strategic shifts in its major clients’ business decisions to terminate online cooperation of third-party companies and unfavorable changes in domestic industry policies. Consequently, FGS’s revenue and active business activities declined precipitously, resulting in zero revenue for fiscal year 2026.

Cost of revenue

Cost of revenues increased from RMB51.0 million for the year ended June 30, 2025 to RMB73.4 million ($10.8 million) for the same period in 2026.

For the years ended June 30, 2025 and 2026, cost of revenue from automation product and software was approximately RMB28.6 million and RMB47.2 million ($7.0 million), respectively, representing an increase of approximately RMB18.6 million ($2.7 million) or 65.0%. The increase in cost of revenue from automation product and software was primarily attributable to increased revenue of automation products and software.

For the years ended June 30, 2025 and 2026, cost of revenue from equipment and accessories was approximately RMB13.2 million and RMB20.4 million ($3.0 million), respectively, representing an increase of approximately RMB7.2 million ($1.1 million) or 54.7%. The increase in costs of revenue was primarily driven by expanded business activity, mirroring the same factor behind the growth in revenue.

For the years ended June 30, 2025 and 2026, cost of revenue from oilfield environmental protection was approximately RMB8.5 million and RMB5.7 million ($0.8 million), respectively, representing a decrease of approximately RMB2.8 million ($0.4 million) or 33.1%. While actively pursuing new business opportunities in a constrained market, the Company undertook testing projects. Given their high uncertainty, equipment costs for these projects were fully expensed upon purchase in the prior period, resulting in lower costs in the current period compared to the prior period.

For the years ended June 30, 2025 and 2026, cost of revenue from platform outsourcing services was approximately RMB0.6 million and nil, respectively, representing a decrease of approximately RMB0.6 million ($0.1 million) or 100.0%. The reason for the decrease is consistent with that of the revenue decline.

Gross profit

Gross profit increased to RMB36.5 million ($5.4 million) for the year ended June 30, 2026 from RMB15.2 million ($2.2 million) for the same period in 2025. Our gross profit as a percentage of revenue increased to 33.2% for the year ended June 30, 2026 from 23.0% for the same period in 2025.

For the years ended June 30, 2025 and 2026, our gross profit from automation product and software was approximately RMB5.5 million and RMB22.5 million ($3.3 million), respectively, representing an increase in gross profit of approximately RMB17.0 million ($2.5 million) or 310.4%. The gross margin expansion to 32.3% was primarily driven by the higher-margin overseas oilfield projects, which contributed RMB44.2 million of revenue, representing approximately 63% of automation segment revenue for fiscal 2026. Excluding the overseas projects, our domestic automation gross margin remained relatively stable.For the years ended June 30, 2025 and 2026, gross profit from equipment and accessories was approximately RMB5.2 million and RMB7.4 million ($1.1 million), respectively, representing an increase of approximately RMB2.2 million ($0.3 million) or 42.4%. The increase in gross profit was consistent with the change in revenue. The gross margin for equipment and accessories has remained relatively stable in this period.For the years ended June 30, 2025 and 2026, gross profit from oilfield environmental protection was approximately RMB1.7 million and RMB6.6 million ($1.0 million), respectively, representing an increase of RMB4.9 million ($0.7 million) or 288.2%. The lower gross profit in fiscal 2025 was mainly due to testing projects, where the related equipment used for these projects was fully expensed as it was consumed during execution, when we were not sure that revenue from these projects could be recognized. The increase in gross margin from 16.9% to 53.4% was mainly attributable to the absence, in fiscal 2026, of the one-time testing project costs that were fully expensed as incurred in fiscal 2025, when revenue recognition for those testing projects remained uncertain. Excluding the impact of such one-time testing costs, the normalized gross margin for fiscal 2025 would have been higher, and the fiscal 2026 margin of 53.4% reflects a normal standard in settlement prices for certain wastewater treatment clients together with a more favorable project mix.For the years ended June 30, 2025 and 2026, gross profit from platform outsourcing services was approximately RMB2.8 million and nil, respectively, representing a decrease of approximately RMB2.8 million ($0.4 million) or 100.0%. The decrease in gross profit was consistent with the change in revenue.

Operating expenses

Selling expenses decreased by 43.6%, or RMB4.1 million ($0.6 million), from RMB9.3 million ($1.4 million) in the year ended June 30, 2025 to RMB5.2 million ($0.8 million) in the same period of 2026.

General and administrative expenses increased by 11.8%, or RMB5.8 million ($0.9 million), from RMB49.6 million ($7.3 million) in the year ended June 30, 2025 to RMB55.4 million ($8.2 million) in the same period of 2026.

Net recovery of credit losses of RMB2.9 million ($0.4 million) for the year ended June 30, 2025 as compared to net provision for credit losses of RMB4.1 million ($0.6 million) for the same period in 2026.

Research and development expenses decreased by 21.7%, or RMB3.6 million ($0.5 million) from RMB16.4 million ($2.4 million) for the year ended June 30, 2025 to RMB12.9 million ($1.9 million) for the same period of 2026.

Loss from operations

Loss from operations was RMB41.2 million ($6.1 million) for the year ended June 30, 2026, compared to a loss of RMB57.3 million ($8.4 million) for the same period of 2025. This RMB16.1 million ($2.4 million) decrease in loss from operations was mainly driven by higher gross profit, as previously discussed.

Change in fair value of warrant liability

The Company classified the warrants issued in connection with common share offering as liabilities at their fair value and adjusted the warrant instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in our statement of operations. Gain in change in fair value of warrant liability was RMB6,226 ($917) and RMB671 ($99) for the years ended June 30, 2025 and 2026, respectively. The primary reason for the decrease in the fair-value gain of the warrant liability was the change in the fair value assessment price.

Interest income

Net interest income was RMB10.9 million ($1.6 million) for the year ended June 30, 2026, compared to net interest income of RMB12.3 million ($1.8 million) for the same period of 2025. The RMB1.4 million ($0.2 million) decrease in net interest income was primarily attributable to the Company’s receipt of partial repayments of loans to third parties, partially offset by interest income from outstanding loans to third parties, during the year ended June 30, 2026.

Other income (expenses), net.

Other net expenses was RMB1.3 million ($0.2 million) for the year ended June 30, 2026, compared to other net income of RMB1.3 million ($0.2 million) for the same period of 2025. The RMB2.6 million ($0.4 million) decrease in other net income was primarily due to the closure of Qinghai BHD and the disposal of 51% equity interest in MSJ, which together resulted in a total loss on equity shares investments of RMB1.1 million. Additionally, following the closure of the Qinghai office, RMB0.6 million in payables that could no longer be settled was recognized as income, RMB0.2 million in receivables that could not be collected was written off as a loss and an increase in foreign exchange transaction expenses of RMB1.0 million due to the fluctuation of exchange rate of RMB against US dollars during the year ended June 30, 2026 compared to the same period of 2025.

Net loss

As a result of the factors described above, net loss was RMB31.6 million ($4.7 million) for the year ended June 30, 2026, a decrease of RMB12.1 million ($1.8 million) from net loss of RMB43.7 million ($6.4 million) for the same period of 2025.

Cash and short-term investment

As of June 30, 2026, we had cash in the amount of approximately RMB29.7 million ($4.4 million) and short-term investment in bank fixed income product of approximately RMB9.0 million ($1.3 million). As of June 30, 2025, we had cash in the amount of approximately RMB98.9 million ($14.6 million) and short-term investment in bank fixed income product of approximately RMB3.6 million ($0.5 million).

About Recon Technology, Ltd (“RCON”)

Recon Technology, Ltd (NASDAQ: RCON) is the People’s Republic of China’s first NASDAQ-listed non-state-owned oil and gas field service company. Recon supplies China’s largest oil exploration companies with advanced automated technologies, efficient gathering and transportation equipment and reservoir stimulation measure for increasing petroleum extraction levels, reducing impurities and lowering production costs. Through the years, RCON has taken leading positions within several segmented markets of the oil and gas field service industry. RCON also has developed stable long-term cooperation relationship with its major clients. Since 2023, Recon also entered into the business of chemical recycling of waste plastic. For additional information please visit: http://www.recon.cn/.

Forward-Looking Statements

Recon includes “forward-looking statements” within the meaning of the federal securities laws throughout this press release. A reader can identify forward-looking statements because they are not limited to historical fact or they use words such as “scheduled,” “may,” “will,” “could,” “should,” “would,” “expect,” “believe,” “anticipate,” “project,” “plan,” “estimate,” “forecast,” “goal,” “objective,” “committed,” “intend,” “continue,” or “will likely result,” and similar expressions that concern Recon’s strategy, plans, intentions or beliefs about future occurrences or results. Forward-looking statements are subject to risks, uncertainties and other factors that may change at any time and may cause actual results to differ materially from those that Recon expected. Many of these statements are derived from Recon’s operating budgets and forecasts, which are based on many detailed assumptions that Recon believes are reasonable, or are based on various assumptions about certain plans, activities or events which we expect will or may occur in the future. However, it is very difficult to predict the effect of known factors, and Recon cannot anticipate all factors that could affect actual results that may be important to an investor. All forward-looking information should be evaluated in the context of these risks, uncertainties and other factors, including those factors disclosed under “Risk Factors” in Recon’s most recent Annual Report on Form 20-F and any subsequent half-year financial filings on Form 6-K filed with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by the cautionary statements that Recon makes from time to time in its SEC filings and public communications. Recon cannot assure the reader that it will realize the results or developments Recon anticipates, or, even if substantially realized, that they will result in the consequences or affect Recon or its operations in the way Recon expects. Forward-looking statements speak only as of the date made. Recon undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances arising after the date on which they were made, except as otherwise required by law. As a result of these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements included herein or that may be made elsewhere from time to time by, or on behalf of, Recon.

RECON TECHNOLOGY, LTD

CONSOLIDATED BALANCE SHEETS

As of June, 30

As of June, 30

As of June, 30

2025

2026

2026

RMB

RMB

US Dollars

ASSETS

Current assets

Cash

¥

98,874,577

¥

29,745,574

4,383,955

Restricted cash

8,204

104

16

Short-term investments

3,599,211

9,005,007

1,327,174

Notes receivable

—

200,000

29,476

Accounts receivable, net

35,852,484

46,142,449

6,800,555

Inventories, net

1,344,588

1,330,874

196,147

Other receivables, net

3,760,881

9,879,518

1,456,061

Other receivables – related parties

67,976

400,000

58,953

Loans to third parties-short term

141,564,073

46,358,973

6,832,467

Purchase advances, net

14,619,556

57,757,856

8,512,455

Contract costs, net

53,547,408

25,059,648

3,693,335

Prepaid expenses

389,216

801,617

118,140

Prepaid consideration for acquisition of noncontrolling interest

—

1,950,000

287,394

Deferred offering cost

2,529,724

339,255

50,000

Total Current Assets

356,157,898

228,970,875

33,746,128

Property and equipment, net

19,986,635

17,158,744

2,528,886

Construction in progress

12,000,900

86,366,301

12,728,818

Investment in unconsolidated entity, net

—

1,824,974

268,968

Loans to third parties-long term

118,500,000

283,684,309

41,809,894

Operating lease right-of-use assets, net (including ¥696,851 and ¥2,481,013 ($365,656) from related parties as
   of June 30, 2025 and June 30, 2026, respectively)

18,975,692

21,441,571

3,160,097

Total Assets

¥

525,621,125

¥

639,446,774

$

94,242,791

LIABILITIES AND EQUITY

Current liabilities

Short-term bank loans

¥

11,582,336

¥

11,306,258

$

1,666,336

Accounts payable

19,398,669

36,902,581

5,438,767

Other payables

6,154,889

3,430,099

505,534

Other payable- related parties

2,927,377

649,559

95,733

Contract liabilities

4,719,255

1,669,736

246,089

Contract liabilities- related parties

—

400,000

58,953

Accrued payroll and employees’ welfare

3,212,227

4,927,089

726,163

Taxes payable

795,629

1,481,308

218,318

Short-term borrowings – related parties

10,017,250

20,033,917

2,952,634

Operating lease liabilities – current (including ¥355,601 and ¥1,682,080 ($247,908) from related parties as of
   June 30, 2025 and June 30, 2026, respectively)

1,761,231

2,924,605

431,033

Total Current Liabilities

60,568,863

83,725,152

12,339,560

Operating lease liabilities – non-current (including nil and ¥1,026,433 ($151,278) from related parties as of
   June 30, 2025 and June 30, 2026, respectively)

1,081,827

3,291,220

485,066

Long-term borrowings – related party

10,000,000

—

—

Warrant liability – non-current

688

—

—

Total Liabilities

71,651,378

87,016,372

12,824,626

Commitments and Contingencies

Shareholders’ Equity

Class A ordinary shares, $0.02 U.S. dollar par value, 2,500,000 shares authorized and $0.02 U.S. dollar par
   value, 15,000,000 shares authorized as of June 30, 2025 and June 30, 2026, respectively; 53,154 shares and
   353,154 share issued and outstanding as of June 30, 2025 and June 30, 2026, respectively *

101,548

142,646

21,023

Class B ordinary shares, $0.0001 U.S. dollar par value, 80,000,000 authorized shares and $0.0001 U.S. dollar
   par value, 200,000,000 shares authorized as of June 30, 2025 and June 30, 2026, respectively; 20,000,000
   shares and 20,000,000 shares issued and outstanding as of June 30, 2025 and June 30, 2026, respectively

14,038

14,038

2,069

Additional paid-in capital

692,569,747

827,448,759

121,950,857

Statutory reserve

4,148,929

4,148,929

611,476

Accumulated deficit

(262,900,639)

(292,560,687)

(43,118,110)

Accumulated other comprehensive income

33,493,895

27,133,454

3,998,976

Total Recon Technology, Ltd’ equity

467,427,518

566,327,139

83,466,291

Non-controlling interests

(13,457,771)

(13,896,737)

(2,048,126)

Total shareholders’ equity

453,969,747

552,430,402

81,418,165

Total Liabilities and Shareholders’ Equity

¥

525,621,125

¥

639,446,774

$

94,242,791

* Retrospectively restated for the 1-for-200 reverse stock split on August 18, 2026.

 

 

RECON TECHNOLOGY, LTD

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

For the years ended

June 30, 

2024

2025

2026

2026

RMB

RMB

RMB

US Dollars

Revenue

¥

68,854,280

¥

66,285,032

¥

109,898,245

$

16,196,997

Cost of revenue

47,976,836

51,044,495

73,410,205

10,819,325

Gross profit

20,877,444

15,240,537

36,488,040

5,377,672

Selling and distribution expenses

10,374,388

9,343,480

5,267,001

776,260

General and administrative expenses

63,765,583

49,645,680

55,495,066

8,178,961

Allowance for (net recovery of) credit losses

4,086,505

(2,856,803)

4,094,917

603,516

Research and development expenses

14,288,879

16,427,892

12,858,639

1,895,129

Operating expenses

92,515,355

72,560,249

77,715,623

11,453,866

Loss from operations

(71,637,911)

(57,319,712)

(41,227,583)

(6,076,194)

Other income (expenses)

Subsidy income

131,428

85,762

37,185

5,480

Interest income

22,897,763

13,390,041

11,944,760

1,760,440

Interest expense

(1,070,449)

(1,110,984)

(1,041,518)

(153,501)

Loss from investment in unconsolidated entity

—

—

(1,102,361)

(162,468)

Loss (gain) in fair value changes of warrants liability

(933,995)

6,226

671

99

Foreign exchange transaction gain (loss)

(881,695)

952,815

(79,217)

(11,675)

Other income

59,049

296,155

(178,542)

(26,314)

Other income, net

20,202,101

13,620,015

9,580,978

1,412,061

Loss before income tax

(51,435,810)

(43,699,697)

(31,646,605)

(4,664,133)

Income tax expenses (benefits)

30

1,580

(1,609)

(237)

Net loss

(51,435,840)

(43,701,277)

(31,644,996)

(4,663,896)

Less: Net loss attributable to non-controlling interests

(1,564,581)

(1,112,723)

(1,984,948)

(292,545)

Net loss attributable to Recon Technology, Ltd

¥

(49,871,259)

¥

(42,588,554)

¥

(29,660,048)

$

(4,371,351)

Comprehensive loss

Net loss

(51,435,840)

(43,701,277)

(31,644,996)

(4,663,896)

Foreign currency translation adjustment

2,009,476

(3,642,754)

(6,360,441)

(937,413)

Comprehensive loss

(49,426,364)

(47,344,031)

(38,005,437)

(5,601,309)

Less: Comprehensive loss attributable to non- controlling interests

(1,564,581)

(1,112,723)

(1,984,948)

(292,545)

Comprehensive loss attributable to Recon Technology, Ltd

¥

(47,861,783)

¥

(46,231,308)

¥

(36,020,489)

$

(5,308,764)

Net loss per share – basic and diluted*

¥

(1,974.16)

¥

(936.18)

¥

(266.52)

$

(39.28)

Weighted – average shares – basic and diluted*

25,262

45,492

111,286

111,286

* Retrospectively restated for the 1-for-18 reverse stock split effective on May 1, 2024 and 1-for-200 reverse stock split on August
18, 2026.

 

 

RECON TECHNOLOGY, LTD

CONSOLIDATED STATEMENTS OF CASH FLOWS

For the years ended June 30,

2024

2025

2026

2026

RMB

RMB

RMB

US Dollars

Cash flows from operating activities:

Net loss

¥

(51,435,840)

¥

(43,701,277)

¥

(31,644,996)

$

(4,663,896)

Adjustments to reconcile net income (loss) to net cash used in operating activities:

Depreciation and amortization

2,844,025

3,147,936

2,870,387

423,043

Loss from disposal of property and equipment

35,325

12,410

314

46

(Gain) loss in fair value changes of warrants liability

933,995

(6,226)

(671)

(99)

Allowance for (net recovery of) credit losses

4,086,505

(2,856,803)

4,094,917

603,516

Allowance (reversal) for slow moving inventories

886,991

(1,251,279)

(30,722)

(4,528)

Amortization of right of use assets

1,636,215

4,571,501

2,915,356

429,670

Restricted shares issued for management and employees

22,427,682

10,279,881

12,687,016

1,869,835

Restricted shares issued for services

1,070,143

—

—

—

Loss from investment in unconsolidated entity

—

—

1,102,361

162,468

Cash position changes due to the decrease of ownership interest

—

—

(32,811)

(4,836)

Accrued interest income from loans to third parties

(6,998,866)

(5,288,121)

(9,116,577)

(1,343,617)

Accrued interest income from short-term investment

(885,394)

(17,411)

(5,007)

(738)

Expensing of deferred financing costs

—

—

2,529,724

372,835

Changes in operating assets and liabilities:

Notes receivable

2,400,570

1,341,820

(200,000)

(29,476)

Accounts receivable

(12,151,359)

1,686,887

(12,107,973)

(1,784,494)

Inventories

5,590,058

267,413

(28,080)

(4,138)

Other receivables

31,908

(531,445)

(5,840,026)

(860,713)

Other receivables-related parties

(275,976)

208,000

(332,024)

(48,934)

Purchase advances

(2,422,123)

(5,057,967)

(43,515,113)

(6,413,334)

Contract costs

(4,400,442)

(363,721)

29,704,410

4,377,888

Prepaid expense

(51,467)

12,370

(412,401)

(60,781)

Operating lease liabilities

(2,907,014)

(4,869,474)

(2,008,468)

(296,012)

Accounts payable

(604,203)

1,940,574

(4,208,390)

(620,240)

Other payables

(3,020,216)

3,399,579

(2,645,098)

(389,839)

Other payables-related parties

(293,326)

628,308

(2,277,818)

(335,709)

Contract liabilities

(927,884)

2,898,774

(3,049,519)

(449,443)

Contract liabilities-related parties

—

—

400,000

58,953

Accrued payroll and employees’ welfare

854,644

(24,937)

1,714,862

252,739

Taxes payable

(171,884)

(197,966)

634,382

93,496

Net cash used in operating activities

(43,747,933)

(33,771,174)

(58,801,965)

(8,666,338)

Cash flows from investing activities:

Investment in unconsolidated entity

—

—

(700,000)

(103,167)

Purchases of property and equipment

(282,184)

(1,010,812)

(307,295)

(45,290)

Proceeds from disposal of property and equipment

20,000

2,000

3,580

528

Purchase of land use right

(15,000,251)

—

—

—

Repayments of loans to third parties

117,522,129

100,478,982

96,417,165

14,210,132

Payments made for loans to third parties

(196,437,504)

(140,490,800)

(166,200,000)

(24,494,849)

Payments and prepayments for construction in progress

(219,132)

(8,924,101)

(52,653,099)

(7,760,107)

Payments for short-term investments

(203,481,600)

(3,581,800)

(9,000,000)

(1,326,436)

Redemption of short-term investments

300,863,518

87,239,515

3,496,550

515,328

Net cash (used in) provided by investing activities

2,984,976

33,712,984

(128,943,099)

(19,003,861)

Cash flows from financing activities:

Proceeds from short-term bank loans

11,581,000

10,476,000

15,305,000

2,255,678

Repayments of short-term bank loans

(11,632,755)

(11,319,623)

(15,582,198)

(2,296,532)

Proceeds from short-term borrowings-related parties

10,000,000

—

—

—

Repayments of short-term borrowings-related parties

(10,018,222)

—

—

—

Proceeds from sale of ordinary shares, net of issuance costs

77,711,533

(2,529,724)

121,893,839

17,964,929

Redemption of warrants

(32,617,499)

—

—

—

Payments to Acquire noncontrolling interests

—

—

(1,950,000)

(287,394)

Capital contribution by controlling shareholders

—

100,000

—

—

Net cash (used in) provided by financing activities

45,024,057

(3,273,347)

119,666,641

17,636,681

Effect of exchange rate fluctuation on cash and restricted cash

1,722,165

(8,626,292)

(1,058,680)

(156,030)

Net increase (decrease) in cash and restricted cash

5,983,265

(11,957,829)

(69,137,103)

(10,189,548)

Cash and restricted cash at beginning of year

104,857,345

110,840,610

98,882,781

14,573,519

Cash and restricted cash at end of year

¥

110,840,610

¥

98,882,781

¥

29,745,678

$

4,383,971

Reconciliation of cash and restricted cash, beginning of year

Cash

¥

104,125,800

¥

109,991,674

¥

98,874,577

$

14,572,310

Restricted cash

731,545

848,936

8,204

1,209

Cash and restricted cash, beginning of year

¥

104,857,345

¥

110,840,610

¥

98,882,781

$

14,573,519

Reconciliation of cash and restricted cash, end of year

Cash

¥

109,991,674

¥

98,874,577

¥

29,745,574

$

4,383,955

Restricted cash

848,936

8,204

104

16

Cash and restricted cash, end of year

¥

110,840,610

¥

98,882,781

¥

29,745,678

$

4,383,971

Supplemental cash flow information

Cash paid during the year for interest

¥

659,472

¥

1,070,781

¥

1,042,505

$

153,646

Cash paid during the year for income tax

¥

—

¥

1,609

¥

—

$

—

Non-cash investing and financing activities

Right-of-use assets obtained in exchange for operating lease obligations

¥

8,303,099

¥

—

¥

6,752,841

$

995,246

Reduction of right-of-use assets and operating lease obligations due to early termination of lease agreement

¥

61,301

¥

1,886,347

¥

1,371,606

$

202,150

Payable for construction in progress

¥

—

¥

7,270,577

¥

21,712,302

$

3,199,997

Capital contribution receivable due from non-controlling Interest

¥

—

¥

724,408

¥

—

$

—

Investment in unconsolidated entity resulting from transfer out of control

¥

—

¥

—

¥

1,124,974

$

165,801

 

View original content:https://www.prnewswire.com/news-releases/recon-technology-ltd-reports-financial-year-results-for-fiscal-year-2026-302894412.html

SOURCE Recon Technology, Ltd

Continue Reading

Technology

Switch Bioworks Secures Brazil Approval, Strengthening Its Global Position in Engineered Agricultural Microbes

Published

on

By

Approval moves Switch toward Brazil field evaluation, adding a major biologicals market and a new testing window to accelerate data generation and product development 

SAN CARLOS, Calif., Sept. 30, 2026 /PRNewswire/ — Switch Bioworks, a deep-tech biotechnology company building programmable microbes, today announced that Brazil’s National Technical Biosafety Commission (CTNBio) has approved the company’s dossiers, advancing Switch toward field testing of its engineered nitrogen-fixing microbes in one of the world’s largest agricultural markets and one of the most advanced markets for biological inputs. Brazil’s complementary growing seasons create the potential for additional field-learning cycles each year, accelerating data generation and product development. The milestone builds on Switch’s U.S. regulatory and field progress and research in Kenya, expanding development of a new category of biofertilizer across three continents.

Nitrogen fertilizer is essential to crop production globally, but conventional production relies on the energy-intensive Haber-Bosch process and remains vulnerable to global energy, price and supply disruptions. Switch’s platform is built on making nitrogen with biology, following a simple principle: grow first, produce second. Its genetic switches allow microbes to establish on plant roots before activating nitrogen production, addressing the fundamental energy trade-off that has long constrained biological nitrogen fixation. In laboratory studies, Switch’s switchable microbes fixed approximately five times as much nitrogen on plants as always-on controls. The company is now testing that architecture in the field to understand how it performs across environments and real agricultural practices.

Switch currently has active field work in the United States and Kenya. In the United States, USDA- and EPA-authorized multi-site corn field trials are evaluating the technology across six states in the Midwest. In Kenya, Switch is testing several microbial candidates in smallholder farming systems with local research partners, broadening the scope of its development program. Future field testing in Brazil extends that work into South America.

Brazil represents both a significant market opportunity and a valuable development environment for Switch. As the world’s largest exporter of soybeans and a top-three corn producer, the country combines enormous agricultural scale with one of the world’s most advanced markets for biological inputs. Its soils, farm-management practices and climate also differ from Switch’s current field work, creating a new setting to test the same genetic-control platform. Brazilian growers are exposed to volatility in global nitrogen fertilizer markets, underscoring the potential value of biological technologies that could ultimately provide an additional source of nitrogen produced closer to where crops need it. Based on publicly available information, Switch represents a new category of biological fertilizer in Brazil: an intergeneric genetically engineered microbe designed to live and function in the field.

“Brazil is a global powerhouse in agricultural biologicals, with world-class research, commercial scale and strong farmer adoption,” said Tim Schnabel, founder and CEO of Switch Bioworks. “Adding Brazil gives us a new regulatory pathway and the opportunity to demonstrate how programmable microbes perform consistently across distinct agricultural environments. Each new geography we add to our development program accelerates our learning and strengthens the infrastructure needed to deploy this technology globally.”

Switch’s core genetic-switch technology is covered by seven patent families. Nitrogen fertilizer is the first application for a broader platform designed to enable programmable microbes to perform specific functions in complex, real-world environments beyond traditional fermentation systems. Switch is building toward a future where manufacturing is no longer confined to factories—where programmable microbes make what we need, where we need it, when we need it.

About Switch Bioworks

Switch Bioworks is a Stanford spinout and deep-tech biotechnology company building genetic control systems for programmable microbes. Its switches direct when microbes grow and when they produce, allowing them to establish in complex, real-world environments before activating a useful function. Switch is proving the platform first in agriculture, where engineered microbes are designed to establish on crop roots and then produce nitrogen where plants can use it. In grow-room studies, switchable strains fixed approximately five times more nitrogen on plants than always-on controls. USDA- and EPA-authorized multi-site corn field trials are evaluating the technology under real agricultural conditions. The core genetic-switch technology is covered by seven patent families, and Switch was selected for ARPA-E’s TEOSYNTE program. Nitrogen is the first proving ground for a broader platform for biological production at the point of need. Learn more at www.switchbioworks.com.

Media Contact
Sarah McAllister
423469@email4pr.com
+1 (212) 220-6045

View original content to download multimedia:https://www.prnewswire.com/news-releases/switch-bioworks-secures-brazil-approval-strengthening-its-global-position-in-engineered-agricultural-microbes-302893787.html

SOURCE Switch Bioworks

Continue Reading

Trending